← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Enzymes
olipudase alfa
A16AB25
Forms & Strengths
- Solution for injection: 1mg/mL
- Single-dose vial: 1mL, 2mL
Adult Dosing
- Initial dose: 1mg/kg
- Maintenance dose: 1mg/kg every 2 weeks
- Dose adjustment: based on clinical response and tolerability
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Use in pediatric patients is not recommended
Indications
- Treatment of acid sphingomyelinase deficiency (ASMD)
- Long-term enzyme replacement therapy in adult patients with non-central nervous system manifestations of ASMD
Mechanism of Action
- Recombinant human acid sphingomyelinase
- Replaces deficient enzyme in patients with ASMD
- Breaks down sphingomyelin in lysosomes
Contraindications
- None
- Hypersensitivity to olipudase alfa or excipients
Adverse Reactions
- Infusion-related reactions
- Headache
- Fatigue
- Nausea
- Dizziness
Drug Interactions
- No dose adjustment needed for concomitant use with other medications
- Monitor for increased risk of infusion-related reactions with concomitant use of immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use